ICI-85966
Chemical compound
ICI-85966 is a chemical compound that was developed as a potential pharmaceutical agent. It is classified as a serotonin receptor antagonist, specifically targeting the 5-HT2 receptor subtype. This compound was investigated for its potential use in treating various conditions related to serotonin dysregulation, such as anxiety disorders, depression, and schizophrenia.
Chemical Properties[edit | edit source]
ICI-85966 is a synthetic compound with a complex chemical structure. The molecular formula of ICI-85966 is C21H26ClN3O2. The compound features a chlorinated aromatic ring, which is a common motif in many pharmacologically active compounds. The presence of nitrogen atoms in its structure suggests that it can form hydrogen bonds, which may influence its binding affinity to the serotonin receptors.
Pharmacology[edit | edit source]
ICI-85966 acts as an antagonist at the 5-HT2 receptor, a subtype of the serotonin receptor family. The 5-HT2 receptors are G protein-coupled receptors that play a significant role in the modulation of neurotransmission in the central nervous system. By blocking these receptors, ICI-85966 can potentially alter the effects of serotonin, a neurotransmitter involved in mood regulation, perception, and cognition.
Mechanism of Action[edit | edit source]
The mechanism of action of ICI-85966 involves the inhibition of serotonin binding to the 5-HT2 receptors. This blockade can lead to a decrease in the downstream signaling pathways that are typically activated by serotonin. As a result, the compound may exert anxiolytic and antipsychotic effects, making it a candidate for the treatment of psychiatric disorders.
Development and Research[edit | edit source]
ICI-85966 was developed by Imperial Chemical Industries (ICI), a company known for its research in pharmaceuticals and chemicals. Although the compound showed promise in preclinical studies, it did not advance to later stages of clinical development. The reasons for this could include insufficient efficacy, undesirable side effects, or strategic business decisions by the developing company.
Potential Applications[edit | edit source]
While ICI-85966 itself may not have reached the market, the research conducted on this compound has contributed to the understanding of serotonin receptor antagonists. Such compounds continue to be of interest in the development of new treatments for mental health disorders. The study of ICI-85966 has provided insights into the design of more effective and selective serotonin receptor antagonists.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD